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Summary Data from a population-based case-control study conducted in Adelaide, South Australia, and
involving 451 case-control pairs, were analysed to determine whether the associations of menstrual,
reproductive, dietary and other factors with risk of breast cancer differed by oestrogen receptor (ER) status.
Data on ER status were available for 380 cases. The proportion of tumours which were ER+ increased with
age, and there was a higher proportion of ER+ tumours in post-menopausal than in premenopausal women.
Both oral contraceptive use (P=0.055) and cigarette smoking (P=0.047) were associated with increased
(unadjusted) risk of ER- cancer, while having little association with risk of ER+ cancer. Most dietary
factors had little association with risk of either cancer type, the main exception being the reduction in risk of
ER- breast cancer with increasing beta-carotene intake (P for trend=0.017). In general, however, links with
the factors examined were not strong enough to suggest different causal pathways for ER- and ER+ breast
cancer.
Determination of oestrogen receptor status is used to predict
the likely response of breast cancer to hormonal therapy and
also has prognostic value (Hawkins et al., 1980). Oestrogen
receptors have been detected in 50-70% of breast cancer
patients (Stanford et al., 1986); two-thirds of oestrogen
receptor positive (ER+) patients can be expected to respond
to endocrine therapy compared to less than 10% of patients
classified as oestrogen receptor negative (ER-) (Mohla et
al., 1982).
ER+ and ER- breast cancers differ in their biological
properties. However, it has not yet been established whether
ER status reflects different stages of the same disease or two
different forms of the disease with separate causes (Stanford
et al., 1986). Complete absence of overlap between risk
factors for the two types of breast cancer would provide
evidence against a progression from one to the other, while
overlap would suggest either that there is a progression or
that they are independent outcomes with overlapping aetio-
logies. The few case-control studies conducted to date
(Hildreth et al., 1983; McTiernan et al., 1986; Hislop et al.,
1986, 1988; Stanford et al., 1987) suggest that there is some
overlap in risk factors for ER+ and ER- breast cancer.
This possibility, and the others outlined above, are investi-
gated further in the population-based case-control study
reported here, in which risk of ER+ and ER- breast cancer
is examined in association with menstrual and reproductive
history, dietary intake and other factors.
Materials and methods
Study subjects
A detailed description of the study methods has been
presented elsewhere (Rohan et al., 1988). Cases were women
whose histologically confirmed first diagnosis of breast
cancer was reported to the South Australian Central Cancer
Registry between April 1982 and July 1984, who were
between 20 and 74 years old at diagnosis and who were
residing in the Adelaide metropolitan area and registered on
the electoral roll. Of 559 eligible cases, 451 were successfully
interviewed; of those not included, 15 died before interview
could be arranged, 44 were deemed by the attending surgeon
to be unfit for interview, 44 refused to be interviewed, and 5
were untraceable. Controls were women who had no history
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of breast cancer, who were also resident in the Adelaide
metropolitan area and who were registered on the electoral
roll. (In South Australia, 97.2% of persons eligible to vote
are registered (Australian Electoral Office, 1983).) For each
case, one control, matched as closely as possible to the age
of the case at diagnosis, was selected at random from the
electoral roll. A total of 648 individuals were approached in
order to enrol 451 controls. The total study population
therefore comprised 451 case-control pairs. Reasons for non-
participation were recorded during the recruitment of the
first 100 controls, which required attempting to recruit 151
persons. Of the 51 who did not participate, 39 refused, 11
were untraceable and one had died.
Data collection procedure
Subjects were interviewed in their own homes by trained
interviewers whose performance was monitored regularly.
Interviewers were assigned randomly to case-control pairs.
For cases, the average interval between diagnosis and inter-
view was 4.8 months. Each control was interviewed as soon
as possible after her case had been enrolled and in a few
instances interview of the control preceded that of her case.
Approximately 90% of controls were interviewed within two
months of the corresponding case. Matching on date of
interview was introduced in an attempt to minimise dietary
differences between cases and controls due to seasonal
influences.
Socio-demographic and medical information was collected
by use of an interviewer-administered questionnaire which
sought basic biographic information, personal medical
history, family history of cancer, gynaecological and repro-
ductive history and history of hormone use.
Information on usual dietary intake was collected from the
study participants by means of a self-administered quanti-
tative food frequency questionnaire. The questionnaire,
which was designed to ascertain total daily intake of energy,
several nutrients, alcohol and methylxanthines, has been
described in detail elsewhere (Baghurst & Baghurst, 1981;
Baghurst and Record, 1983). Briefly, the questionnaire
allowed recording of the usual frequency of consumption of
179 specified dietary items; provided space for participants
to indicate whether their usual serving size for an item
differed from that of a specified standard serving size
(Baghurst & Record, 1983; Thomas & Corden, 1970), and
also provided space for them to indicate consumption of
other items not listed in the main body of the questionnaire.
Additional data recorded and used in the derivation of
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estimates of nutrient and energy intake (see below) included
information on cooking practices; use of sugar, salt and fat;
and bread type.
Data on the frequency of consumption of food items were
converted to daily nutrient, alcohol, methylxanthine and
energy intake by a computerised dietary analysis system
(Baghurst & Baghurst, 1981; Baghurst & Record, 1984). The
food frequency questionnaire has been shown to provide
estimates of nutrient and energy intake which are repeatable
(Rohan et al., 1987), and which are similar to those derived
from studies in Australia in which dietary records have been
used (Baghurst & Baghurst, 1981). A similar food frequency
questionnaire has been shown to have repeatability and
criterion validity (Willett et al., 1985).
Preparation of tumour cytosol fractions
Frozen tumour tissue was powdered by percussion and then
homogenised (ultraturrax) in ice-cold buffer containing 10M
Tris, 1.5 M EDTA, 1 mM dithiothreitol, 10% glycerol and
20mM sodium molybdate, pH 7.4. The final cytosol fractions
were obtained by centrifugation of the homogenates at
105,000g for 1 h at 4°C.
Hormone receptor determination
Receptor levels for oestrogen and progesterone (results not
shown - see below) were measured using saturation analysis
assays. Five incubation concentrations, ranging from 0.05 to
2.0nM for 3H-oestradiol and from 0.08 to 8.0nM for 3H-
R5020, were used to determine the total ER and progester-
one receptor (PR) binding, respectively, to the tumour
cytosol fraction. Parallel series of incubations containing the
radioligands in the presence of a 100-fold excess of appro-
priate unlabelled ligand (diethylstilboestrol for 3H-oestradiol
and R5020 for 3H-R5020) were used to estimate the levels of
non-specific binding. Incubations were conducted in dupli-
cate, in microtitre plates, with a final incubation volume of
100pl. Following a 16h incubation at 4°C, bound and free
hormone were separated by the addition of dextran-coated
charcoal. Binding data were analysed according to the
method of Scatchard, with least squares linear regression
analysis (Horsfall et al., 1986).
Receptor concentrations were expressed as fmol mg 1
cytosol protein. Tumour cytosols with a receptor concen-
tration equal to or greater than 10fmolmg- 1 protein were
graded as positive in this study. This cut-off was applied to
both ER and PR concentrations. All of the assays were
performed in one laboratory.
Statistical analysis
ER status was determined for 380 cases, PR for 377. No
difference with respect to socio-demographic characteristics
and the examined risk factors was found between those for
whom ER status was known and those for whom it was
unknown (for example - years of education (X2= 0.138,
P=0.933), age (X2=6.82, P=0.146), menopausal status
(X2 =0.69, P=0.406), family history (X2= 0.042, P=0.838)
and oral contraceptive (OC) use (x2=0.07, P=0.791).
Two types of analyses were used to study the association
between risk factors and ER status. In one, cases only were
employed in logistic regression models in which ER status
(ER+ versus ER-) was used as the response variable. This
strategy was used to examine the associations of age and
menopausal status with risk of ER+ versus ER- breast
cancer. (The criteria used to define menopausal status have
been described elsewhere (Rohan et al., 1988).) It was also
used to determine whether the associations between the
factors of interest and risk of breast cancer differed by ER
status; for this purpose, the change in deviance associated
with the addition of the factor to the model formed a x2 test
on n -1 degrees of freedom, where n is the number of levels
at which the factor was examined. The remaining analysis
involved case-control comparisons conducted within strata
defined by ER status. For these analyses, conditional logistic
regression models (Breslow & Day, 1980) were used to derive
relative risks (RR) and 95% confidence intervals (CI) for the
association between the factors of interest and (ER+ or
ER-) breast cancer. The univariate association of each
factor was examined before the effects of potential con-
founders were assessed in multiple conditional logistic regres-
sion models. Interactions with menopausal status were also
examined, and the only interaction which was statistically
significant was that for cigarette smoking. -All- tests of
statistical significance were two-sided.
Factors studied included menstrual and reproductive
factors, family history of breast cancer in a first-degree
relative, previous benign breast disease, hormone use, cigar-
ette smoking and several dietary factors. Analyses for nutri-
ents were based initially on unadjusted estimates of intake
and were then repeated after adjusting these estimates for
caloric intake by the method of Willett et al. (1985). For
these analyses the dietary factors were categorised by tertiles
derived from their distribution in the controls.
ER concentration was positively associated with age (see
below), and therefore analyses were repeated using age-
adjusted values for ER concentration. The results of these
analyses differed little from those based on the unadjusted
values, and only the latter are presented here. Also, ER and
PR status were strongly correlated (62% of ER+ tumours
were PR+, and 78% of ER- tumours were PR-).
Therefore, results based on PR status were similar to those
based on ER status, and only the latter are presented.
Results
Age and menopausal status
Of the 380 cases for whom ER status was determined, 251
were ER+ and 129 were ER-. Table I, which displays the
distribution of cases by ER status, age and menopausal
status, shows that the proportion of breast cancers which
were ER+ increased with age. A logistic regression model
fitted to case data only showed tumours to be 4.52 times
more likely to be ER+ in the oldest age group than in the
youngest (95% CI 2.26-9.09). Table I also shows that there
was also a strong relationship between ER status and
menopausal status, with 74.0% of post-menopausal cancers
being ER+ compared to 52.1% of premenopausal cancers.
In further logistic modelling using the case data only, ER
status had a statistically significant association with meno-
pausal status when the latter was fitted independently; ER+
breast cancer was 2.61 times more common in postmeno-
pausal than in premenopausal women (RR 2.61, 95% CI
1.65-4.14). However, neither age nor menopausal status
added significantly to the model once the other had been
fitted. These patterns were also observed in analyses in
which the actual ER concentration of the tumour was used
(with log1o ER concentration as the response variable).
In an attempt to separate the effects of age and meno-
pausal status, the effect of menopausal status was studied in
women aged 45-54 years, the only age group containing
both premenopausal (47 cases) and post-menopausal (32
cases) women. In this age group, menopausal status was not
associated with altered risk of either ER+ or ER- breast
cancer.
Menstrual and reproductive factors
Risk of ER+ breast cancer increased (albeit not significantly)
with age at first full-term pregnancy, risk for nulliparous
women being slightly less than that for women with a first
full-term pregnancy at 30 years of age or later (Table II).
For ER- breast cancer, nulliparous women and women
with a first full-term pregnancy at age 20 or later were all at
increased risk (relative to the risk for women with an early
first full-term pregnancy), but there was no evidence of a
linear relationship between age at first full-term pregnancyOESTROGEN RECEPTOR STATUS 121
Table I Distribution of breast cancer cases by ER status, age and menopausal status
Premenopausal cases Post-menopausal cases Total
Age ER+ ER- ER+ ER- ER+ ER-
20-44 34 (47.2%) 38 (52.8%) 2 (100%) 0 36 (48.7%) 38 (51.3%)
45-54 28 (59.6%) 19 (40.4%) 22 (68.8%) 10 (31.2%) 50 (63.3%) 29 (36.7%)
55-64 0 0 81 (69.8%) 35 (30.2%) 81 (69.8%) 35 (30.2%)
65-74 0 0 71 (80.7%) 17 (19.3%) 71 (80.7%) 17 (19.3%)
Total 62 (52.1%) 57 (47.9%) 176 (74%) 62 (26.1%) 238 (66.7%) 119 (33.3%)
Of the 380 cases for whom ER status was determined, 22 (12 ER+ and 10 ER-) were deemed to be perimenopausal, while for
the remaining individual menopausal status could not be determined; per cent distribution is shown in parentheses.
Table II Relative risk of ER+ and ER - breast cancer by menstrual and reproductive factors
ER+
Level
No. of No. of
cases controls
<20 30
20-24 69
25-29 80
>29 66
Nulliparous 5
P value for linear trend
Nulliparous 39
1 43
2 61
>2 107
P value for linear trend
0 73
1-12 108
>12 69
P value for linear trend
<13 90
13 60
>13 97
P value for linear trend
<47 57
47-50 49
>50 65
P value for linear trend
27
81
68
69
S
35
27
70
118
67
114
69
90
63
94
71
51
51
RR (95% CI)
1 .oa
1.07 (0.54-2.11)
1.26 (0.64-2.49)
1.55 (0.69-3.48)
1.44 (0.67-3.11)
0.206
1 .oa
1.42 (0.74-2.72)
0.80 (0.46-1.37)
0.82 (0.48-1.40)
0.146
1.oa,b,c
0.97b (0.54-1.72)
1.05b (0.59-2.10)
0.83
1 .oa
0.93 (0.58-1.50)
1.03 (0.59-2.10)
0.965
1..a,id
1.28 (0.76-2.16)
1.85 (1.04-3.29)
0.034
ER-
No. of No. of
cases controls
10
52
43
24
1
15
20
38
57
45
60
25
52
36
42
15
24
23
13
43
40
33
1
15
15
47
53
39
61
30
43
37
50
23
22
25
P value for
test of
difference
between
RR (95% CI) ER groups
1 .Oa
2.42 (0.99-5.90)
1.15 (0.47-2.81)
1.25 (0.39-4.01)
1.67 (0.55-5.06)
0.731
1.oa
1.25 (0.45-3.43)
0.81 (0.35-1.91)
0.99 (0.44-2.25)
0.844
1.oa,b,c
0.73b (0.37-1.45)
0.64b (0.29-1.43)
0.28
1 .oa
0.86 (0.60-1.65)
0.76 (0.40-1.44)
0.403
2.35 (0.87-6.38)
1.96 (0.73-5.25)
0.236
0.393
0.403
0.300
0.951
0.259
aReference category. RR estimates for age at first full-term pregnancy, parity total months lactated and age at menarche are adjusted for
menopausal status. Note: RR are matched and cannot be calculated directly from the unmatched distributions of cases and controls shown in
the table; bTotal months lactated is adjusted for menopausal status, parity, age at first birth; cReference category includes nulliparous women;
dRestricted to post-menopausal women.
and risk of breast cancer. A parity of two or more was
associated with a small, statistically non-significant reduction
in risk of ER+ breast cancer, while for ER- breast cancer
only women who had had two full-term pregnancies were at
reduced risk of breast cancer. There was relatively little
variation in the risk of either ER+ or ER- breast cancer
with age at menarche and total duration of lactation,
although there was some suggestion that risk of ER- breast
cancer decreased with increasing duration of lactation and
with age at menarche. Estimates of effect for duration of
lactation were adjusted for parity and age at first birth
(Table IL).
Post-menopausal women were at lower risk of ER+ and
ER - breast cancer than premenopausal women. The risk of
ER+ cancer for post-menopausal women relative to that for
premenopausal women was 0.86 (95% CI 0.29-2.55). The
corresponding relative risk for ER - cancer was 0.29 (0.06-
1.38). A relatively late age at last menstrual period was
associated with increased risk of both ER+ and ER - breast
cancer, and for the former group there was a statistically
significant trend of increasing risk with increasing age at last
menstrual period.
History of benign breast disease and family history of breast
cancer
Women with a history of benign breast disease were at
increased risk of ER + breast cancer and at decreased risk of
ER - breast cancer (Table III). However, the confidence
intervals associated with both estimates of effect were wide.
Also, a family history of breast cancer was associated with
an increased, but statistically non-significant, risk of both
ER+ and ER - tumours (Table III).
Hormone use
Ever use of oral contraceptives (OCs) was not associated
with altered (unadjusted) risk of ER+ breast cancer (RR
0.91, 95% CI 0.56-1.78), but was associated with a (statis-
tically non-significant) 70% increase in (unadjusted) risk of
ER- breast cancer (RR 1.68, 95% CI 0.84-3.35). The
difference between these associations was statistically signifi-
cant (P =0.028). After adjustment for age at first birth,
parity and smoking this difference remained, but the esti-
mate of effect for ER- breast cancer was markedly reduced
(Table III). Ever use of replacement oestrogens was not
associated with statistically significant alterations in the risk
of either cancer type (Table III), although risk of ER-
breast cancer was increased by 80%. For neither type of
exogenous hormone was there a clear pattern of variation in
risk with duration of exposure (results not shown).
Cigarette smoking
Women who had ever smoked cigarettes had an increased
risk of ER- breast cancer (Table III), a marginally statis-
Factor
Age (years)
at first
full-term
pregnancy
Parity
Total months
lactatedb
Age (years)
at menarche
Age (years)
at last
menstrual
period122 J.A. COOPER et al.
Table III Relative risk of breast cancer by selected risk factors
P value for
ER+ ER- test of
difference
No. of No. of No. of No. of between
Factor Level cases controls RR (95% CI) cases controls RR (95% CI) ER groups
History of benign No 235 243 1.Oa 124 122 1.0a 0.439
breast disease Yes 14 6 2.56 (0.90-7.29) 5 8 0.44 (0.09-2.23)
History of breast No 226 234 1.Oa 119 124 l.Oa 0752
cancer in first Yes 24 16 1.60 (0.83-3.09) 11 6 1.49 (0.52-4.26)
degree relative
Ever use of oral Never 161 158 10a b 54 63 1.0a b
contraceptives Ever 88 92 0.88 (0.53-1.46) 76 67 1.33 (0.69-2.55) 0.01
(OCs)
Ever use of Never 205 195 l.oa 105 101 l.Oa
replacement Ever 41 50 0.85 (0.53-1.38) 24 26 1.84 (0.46-2.20) 0.584
oestrogens
Ever smoked Never 149 150 l.Oa 66 82 1.Oa
cigarettes Ever 101 100 0.95 (0.66-1.37) 64 48 1.63 (1.00-2.66) 0.036
Current smoking Never 149 150 1.Oa 66 82 1.oa
status Current 54 46 1.25 (0.78-1.99) 32 28 1.33 (0.71-2.51) 0.150
Ex 47 54 0.88 (0.56-1.38) 32 20 1.89 (0.99-3.64)
aReference category. All RR estimates adjusted for menopausal status. Note: RR are matched and cannot be calculated directly from the
unmatched distributions of cases and controls shown; bEstimates for OC use also adjusted for parity, age at flrst birth and cigarette smoking.
tically significant association which remained after con-
trolling for obesity, hormone use and reproductive factors,
and which differed significantly (P=0.036) from the associa-
tion between cigarette smoking and risk of ER+ breast
cancer. The increase in risk was confined largely to ex-
smokers (defined as women who had last smoked more than
one year ago). For ER- breast cancer there was a statisti-
cally significant interaction between smoking and meno-
pausal status (X2 =3.93, P=0.047), the effect of smoking
being greater among premenopausal women. The risk for
ever smokers relative to that for never smokers was 3.05
(1.29-7.18) for premenopausal women and 1.04 (0.18-5.96)
for post-menopausal women.
Obesity and dietary factors
Relative risks for ER+ and ER - breast cancer by obesity
and by selected dietary factors are shown in Table IV.
Neither obesity, nor intake of protein, fat, alcohol or
methylxanthines was associated with marked alterations in
risk of either cancer type. Risk was slightly increased at the
second level of energy intake for ER+ cancer, and decreased
at the corresponding level for ER - cancer, but these point
estimates were not statistically significant. The main differ-
ences between tumour types were the findings for beta-
carotene and retinol intake, both having stronger associa-
tions with risk of ER - cancer, and relatively little associa-
tion with risk of ER+ breast cancer. A relatively high retinol
intake was associated with a statistically non-significant
increased risk of ER - cancer, risk for the mid-level of
intake differing little from baseline risk. Risk of ER - breast
cancer decreased with increasing beta-carotene intake, a
trend which was statistically significant (P=0.017).
The patterns described above were mostly similar when
the analyses were repeated using nutrient intake adjusted for
total caloric intake. The main differences were for retinol
and beta-carotene intake. For retinol, risk of ER- breast
cancer now increased with increasing intake, risks for
medium and high levels of intake being, respectively, 1.21
(95% CI 0.65-2.25) and 1.70 (0.87-3.33); however, the trend
in risk was not statistically significant (P=0.107). In con-
trast, there were now statistically significant trends of
decreasing risk ofER+ and ER - breast cancerwithincreasing
beta-carotene intake; for ER - breast cancer, relative risks at
medium and high levels of intake were 0.69 (0.38-1.27) and
0.33 (0.16-0.68), respectively (P value for linear trend,
0.002), while for ER+ breast cancer, corresponding relative
risks were 0.78 (0.50-1.21) and 0.60 (0.38-0.94) (P value for
linear trend, 0.024).
Discussion
Possible sources of bias in this study have been discussed in
detail elsewhere (Rohan et al., 1988). In brief, selection bias
may have arisen from non-response by potential cases and
controls. However, included and non-included cases did not
differ in their distributions by socio-demographic (age, socio-
economic grading of area of residence) and tumour charac-
teristics (diameter, number of nodes). Data on the ER status
of the non-included cases are not available, but given the
similar age distributions of the included and non-included
cases, there is no firm evidence that cases were selected by
ER status. Further, although ER data were not available for
all included cases, there were no differences between those
for whom ER status was known and those for whom it was
unknown with respect to socio-demographic characteristics
and the risk factors examined in this study. In the controls,
response rates decreased with age (from 88% in those aged
20-34 years to 61% in those aged 65-74 years). The
consequences of this cannot be predicted, and the possibility
of selection bias cannot be excluded. Misclassification of
subjects with respect to exposure is another important
potential source of bias here. Among cases, there is no a
priori reason to suspect that the likelihood and magnitude of
this differed by ER status.
In this study, age and menopausal status had strong
associations with ER status, ER+ breast cancer being more
common in older than in younger women and more common
in post-menopausal than in premenopausal women. The
same patterns have been observed in many previous studies
(Stanford et al., 1986). Although analyses in the subgroup of
women aged 45-54 years in the present study suggested that
age is the more important of these two confounded factors, a
finding in agreement with the results of several other studies
(e.g. Elwood & Godolphin, 1980; Hulka et al., 1984;
McCarty et al., 1983), separation of the effects of these two
highly correlated variables is difflcult (Stanford et al., 1986).
The reason why the proportion of tumours which are ER+ is
higher in older (post-menopausal) women than in younger
(premenopausal) women is unknown, but may be due to the
lower plasma levels of endogenous oestrogens in the former
group, with consequent relative underoccupation of ER sites,
and also to the lower plasma levels of progesterone in thisOESTROGEN RECEPTOR STATUS 123
Table IV Relative risk of ER+ and ER- breast cancer by obesity and by absolute daily intake of selected dietary factors
P value for
ER+ ER- test of
difference
No. of No. of No. of No. of between
Factor Level cases controls RR (95% CI) cases controls RR (95% CI) ER groups
Quetelet's <22.8 85 89 1.0oa 43 40 1.Oa
index (kgm2) 22.8-26.0 69 76 0.99 (0.64-1.52) 38 46 0.68 (0.36-1.28) 0.472
>26.0 94 83 1.24 (0.79-1.94) 49 42 0.99 (0.55-1.80)
P value for linear trend 0.36 0.94
Energy <6906.7 77 82 1.Oa 48 43 1.Oa
(kJday1) 6906.7-8877.0 92 84 1.20 (0.76-1.88) 33 42 0.73 (0.39-1.36) 0.165
>8877.0 81 84 1.05 (0.80-1.68) 49 45 1.10 (0.61-2.00)
P value for linear trend 0.904 0.813
Protein <68.7 76 90 1.Oa 44 38 1.Oa
(gdayf) 68.7-89.0 84 77 1.25 (0.80-1.89) 34 46 0.69 (0.37-1.28) 0.387
>89.0 90 83 1.31 (0.85-2.03) 52 46 1.10 (0.59-2.04)
P value for linear trend 0.225 0.773
Total fat <66.5 79 84 1.Oa 40 39 1.Oa
(gday 1) 66.5-92.7 89 78 1.21 (0.76-1.91) 47 49 1.04 (0.57-1.92) 0.999
>92.7 82 88 1.31 (0.85-2.03) 43 42 1.15 (0.60-2.19)
P value for linear trend 0.958 0.792
Alcohol Non-drinker 93 96 1.Oa 42 43 1.0a
(gday1) <2.5 44 45 1.02 (0.58-1.77) 22 33 0.56 (0.28-1.12) 0.777
2.5-9.3 45 53 0.89 (0.53-1.89) 27 25 1.06 (0.52-2.21)
>9.3 68 56 1.28 (0.77-2.13) 39 29 1.21 (0.58-2.51)
P value for linear trend 0.440 0.491
Retinol <334.4 90 81 1.oa 40 45 1.Oa
(pgday 1) 334.4-962.8 81 83 0.89 (0.56-1.42) 30 41 0.85 (0.46-1.56) 0.014
>962.8 79 86 0.78 (0.49-1.25) 60 44 1.66 (0.91-3.01)
P value for linear trend 0.394 0.119
Beta-carotene <4152.7 88 82 1.Oa 55 43 1.0a
(pgday1) 4152.7-7196.8 93 77 1.09 (0.71-1.68) 47 41 0.81 (0.44-1.51) 0.427
>7196.8 69 91 0.71 (0.46-1.11) 28 46 0.43 (0.21-0.88)
P value for linear trend 0.182 0.017
Methyl- <233.6 86 84 1.Oa 43 43 1.0a
xanthines 233.6-349.2 72 83 0.95 (0.49-2.04) 40 43 0.95 (0.49-2.04) 0.861
(mgday1) >349.2 92 83 1.26 (0.68-2.31) 47 44 1.26 (0.68-2.31)
P value for linear trend 0.758 0.559
aReference category. All RR estimates adjusted for menopausal status. Note: RR are matched and cannot be calculated directly from the
unmatched distributions of cases and controls shown in the table.
group, with consequent reduction in the inhibitory effect of
progesterone on ER synthesis (Hawkins et al., 1980).
Many of the other factors investigated here were con-
founded by menopausal status and age, and had relatively
weak associations with risk of ER+ and ER- breast cancer.
In this respect, the results presented here are largely in
accord with those of previous case-control studies which
have examined risk factors for breast cancer by ER status
(Hildreth et al., 1983; McTiernan et al., 1986; Hislop et al.,
1986, 1988; Stanford et al., 1987), and the general absence of
statistically significant associations may reflect the relatively
low statistical power of studies to date.
Patterns of risk in association with the variables examined
in the present study were mostly similar for ER+ and ER-
breast cancer (and, in general, this applies also to the results
of previous case-control studies), exceptions being the find-
ings for a history of benign breast disease, for ever use of
oral contraceptives, for cigarette smoking and for intake of
retinol and beta-carotene. The wide confidence intervals
around the point estimates for risk in association with a
history of benign breast disease suggest that, for this variable
at least, chance may provide an explanation for the divergent
results. Nevertheless, results in accord with those observed
here (i.e. increased risk of ER+ breast cancer and decreased
risk of ER- breast cancer) were also reported by Hildreth
et al. (1983).
In the present study, ever use of OCs was associated with
a statistically non-significant increase in the risk of ER-
breast cancer, and with little alteration in the risk of ER+
breast cancer. Results of previous studies are summarised in
Table V. Neither of the previous case-control studies showed
pronounced effects of OCs, while of the four studies involv-
ing breast cancer cases only (Elwood & Godolphin, 1980;
Hulka et al., 1984; Lesser et al., 1981; Osborne et al., 1983),
two (Lesser et al., 1981; Osborne et al., 1983) showed those
who had ever used OCs to be more likely to have ER-
tumours, while the remaining studies showed no difference
between ever and never users of OCs. Collectively, therefore,
studies to date do not provide strong support for an
association between OC use and ER status. It is possible
that this reflects a counterbalancing effect of progesterone on
the effects of oestrogen (Stanford et al., 1986). The present
study also showed a statistically non-significant positive
association between replacement oestrogens and risk of
ER- breast cancer. This observation provides qualified
support for the hypothesis that users of exogenous oestro-
gens are likely to develop ER- breast cancer due to
occupation of binding sites by the exogeneous oestrogen.
Replacement oestrogens and OCs might be expected to differ
in their effects, not only because of absence of progesterone
in the former, but also because synthetic oestrogens (which
are usually present in OCs) are more potent than natural
oestrogens (which are usually used for replacement purposes)
(Longman & Buehring, 1987).
Women who had ever smoked cigarettes had increased
risk of ER- breast cancer, but analtered risk of ER+ breast
cancer. These findings are consistent with an 'anti-
oestrogenic' effect of cigarette smoking, as proposed by
Baron (1984). A possible explanation for this is competitive
binding to oestrogen receptors by a constituent of cigarette
smoke (Baron, 1984). However, the association between
smoking and risk of ER- breast cancer was stronger for ex-124 J.A. COOPER et al.
Table V Oral contraceptives, oestrogen receptor status and breast cancer: a summary
No. of
subjects
Type of Confounding
Reference analysis ER+ ER- variables considered Contrast Results
RR (95% CI)
ER+ ER-
Stanford et al. (1987) Case-control 204 254 race, menopausal status, Ever vs.
family history, benign never used 0.84 (0.58-1.22) 1.22 (0.84-7.75)
breast disease,
quetelet's index
RR (95% CI)
ER+ ER-
McTiernan et al. Case-control 143 97 age Ever vs.
(1986) never used 1.2 (0.74-1.9) 0.82 (0.47-1.4)
Odds of ER+ tumour
Elwood & Godolphin Case only 526 145 age Ever vs.
(1980) never used 0.83 P=0.54
Median receptor level (fmolmg-1)
Hulka et al. (1984) Case only 246 race, age Never used 19.1 P=0.65
Ever used 18.5 P06
Median receptor level (fmolmg-')
Lesser et al. (1981) Case only 397 284 - Never used 11 P<0001
Ever used 6
% ER-
Osborne et al. (1983) Case only 47 71 family history Never used 55% 004
Ever used 70%
smokers, which raises the possibility that hormonal changes
associated with smoking cessation may permanently change
the hormone binding property of malignant tissue. An
alternative explanation for these findings is confounding by
an unmeasured variable.
Obese women are at increased risk of developing breast
cancer (Kelsey, 1979). Additionally, heavy women with
breast cancer have been observed to have poor prognoses
(Donegan et al., 1978; Boyd et al., 1981). It is not known
how obesity exerts these effects, but an influence on endo-
crine status offers a plausible explanation. Obesity is associ-
ated with increased peripheral production of oestrone in
adipose (and other) tissue, and is also associated with
reduced levels of sex hormone-binding globulin, so that
obese women have increased levels of free (bioactive) oestro-
gens (Henderson et al., 1982). Given these endocrine effects
of obesity, and given that oestrogen influences the develop-
ment of its own receptor (Stanford et al., 1986), a relation-
ship between obesity and the ER status of breast tumours
might be anticipated. From a clinical study of 83 women
with breast cancer, Papatestas et al. (1980) reported that
tumours from women of relatively high body weight
(>1501b) had lower ER levels than those from women of
lower weight (< 150lb). They suggested that this observation
might explain the less favourable clinical characteristics of
breast cancer in the obese, and that it might reflect an
underlying role for dietary factors. Results from case-control
studies of obesity, ER status and risk of breast cancer have
not been consistent, however. In the present study, obesity
was associated with very little alteration in the risk of ER+
or ER- breast cancer. Previous studies have shown that
either positive associations between obesity and risk of ER+
and ER- breast cancer (Stanford et al., 1987), or an inverse
association between weight and risk of ER- breast cancer,
with no association between weight and risk of ER+ breast
cancer (Hislop et al., 1986).
The relationship between dietary factors and risk of breast
cancer by oestrogen receptor status has been examined in
only one previous case-control study. Hislop et al. (1988)
found that risk of ER+ and ER- breast cancer increased
with increasing frequency of consumption of various sources
of meat fat, suggesting that if there is a relationship between
dietary fat and risk of breast cancer, it is not mediated by
ER status. There were no clear trends in risk with consump-
tion of green and yellow vegetables. In contrast, in the
present study, while there was no association between
energy, protein or fat intake and risk of ER+ or ER-
breast cancer, some support for an association between diet
and ER status was provided by the results for vitamin A.
Both retinol and beta-carotene were found to have stronger
associations with ER- cancer. Specifically, while retinol and
beta-carotene had weak associations with risk of ER+ breast
cancer, there was a statistically significant reduction in risk
of ER- breast cancer with increasing intake of beta-
carotene, and some suggestion of an increase in risk of ER-
breast cancer at high levels of retinol intake. The latter
finding is contrary to the experimental evidence relating
retinol to reduced risk of cancer (Wald, 1987), and may
represent a chance effect. In contrast, our finding of reduced
risk of ER- breast cancer at high levels of beta-carotene
intake is in accord with the results of the many dietary and
serum studies which have shown an inverse association
between beta-carotene and cancer risk (Wald, 1987). There
is, however, little evidence relating dietary beta-carotene to
risk of breast cancer (Rohan et al., 1988). Study of beta-
carotene is in effect a study of green and yellow vegetable
intake, and it is uncertain whether findings for beta-carotene
reflect a direct effect or an indirect effect of some other
factor associated with beta-carotene (Wald, 1987). Absence
of an association between dietary fat and ER status in the
two case-control studies to date-runs counter to experimental
evidence suggesting higher levels of ER in association with a
relatively high fat intake (Ip & Ip, 1981). Given the sus-
pected role of dietary factors in breast cancer aetiology
(Rohan & Bain, 1987) and in influencing survival from
breast cancer (via an effect on obesity), and given that at
least some dietary factors (and, in particular, dietary fat)
might operate via an influence on ER status (Rohan & Bain,OESTROGEN RECEPTOR STATUS 125
1987), further research into the links between diet and ER
status is warranted, since it might yield preventive and
therapeutic opportunities.
In conclusion, this study has not provided evidence con-
sistent with there being different causal pathways for ER+
and ER- cancer. Indeed, from the results of studies to date,
this seems unlikely, since both tumour types seem to share
risk factors, although some of the risk factors have stronger
associations with one or the other of the two tumour
subtypes (Stanford et al., 1986). These observations are
consistent with the prediction of Moolgavkar et al. (1980)
that malignant breast tumours are initially ER+, but sub-
sequently become hormone independent through clonal evo-
lution. However, the possibility that ER+ and ER- breast
cancers represent independent outcomes with overlapping
aetiologies cannot be excluded.
These data were collected while Dr Rohan was with the
Commonwealth Scientific and Industrial Research Organization
Division of Human Nutrition, Adelaide, Australia. The authors
thank the referees, and Drs John Potter and John Whitehead for
their helpful comments on the manuscript.
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